<DOC>
	<DOC>NCT01706055</DOC>
	<brief_summary>This will be prospective, multicentre, observational study. Patients who will initiate treatment with IFNβ-1b (Betaferon) will be followed up to 6 months. Baseline visit (visit 0) i.e. treatment initiation plus four follow-up visits (visits 1-4). For each patient demographics, medical history data, safety parameters, presence of flu-like symptoms and measures to prevent or treat these symptoms will be collected.</brief_summary>
	<brief_title>Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Diagnosis of relapsingremitting multiple sclerosis (RRMS) according to McDonald (2005) criteria Age &gt;/= 18 years old Treatment MS patients in whom the attending physician has decided to initiate therapy with interferon beta1b; Betaferon Minimum 6 months washout period from previous IFNβ Written Informed Consent signed Patients previously treated with any of the disease modifying drugs (DMDs), with the exception of IFNβ therapy which ended at least 6 months earlier Patients receiving treatment with IFN beta other than Betaferon (Bayer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis (MS)</keyword>
	<keyword>Interferon</keyword>
</DOC>